Bristol-Myers, Watson Settle Pravastatin Suit

Law360, New York (April 24, 2008, 12:00 AM EDT) -- The court overseeing a Novartis AG subsidiary's patent infringement suit against Bristol-Myers Squibb Co. and Watson Pharmaceuticals Inc. over the cholesterol-lowering medication pravastatin has signed off on a settlement agreement bringing the case to a close.

Tuesday, U.S. District Judge T. John Ward signed off on a stipulated order saying that Slovenian generic drug maker LEK D.D.'s claims against Bristol-Myers Squibb and Watson have been dismissed with prejudice, as were the defendants' claims against LEK.

In filing with the U.S. Securities and Exchange Commission, Bristol-Myers Squibb...
To view the full article, register now.